13F Holdings
中文EN

PASG Passage BIO, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1787297 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY26.9%
TTM EPS YoY27.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-212.3%
ROA-69.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets99.8%
Debt / equity0.00x
Current ratio1.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.99x
Accruals ratio-0.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$23.28M$40.18M$61.42M$86.05M$117.67M
SG&A expense$19.88M$24.99M$41.58M$49.34M$60.06M
Operating income-$49.30M-$70.40M-$108.39M-$138.39M-$185.73M
Income tax$0$0———
Net income-$45.52M-$64.77M-$102.06M-$136.12M-$185.39M
EBITDA-$48.57M-$67.32M-$104.67M-$134.72M-$184.19M
EPS (basic)-14.35-21.04-1.86-2.50-3.48
EPS (diluted)-14.35-21.04-1.86-2.50-3.48
Weighted avg. shares (diluted)3.17M3.08M54.74M54.43M53.34M
Balance sheet
Cash & equivalents$46.30M$37.57M$21.71M$34.60M$128.97M
Short-term investments$0$39.18M$92.58M$155.01M$186.81M
Current assets$47.76M$78.81M$117.96M$197.04M$325.07M
PP&E, net$4.11M$9.33M$15.29M$22.52M$23.81M
Total assets$62.28M$102.41M$150.54M$243.55M$355.08M
Current liabilities$23.08M$19.36M$16.34M$18.35M$29.50M
Total liabilities$43.53M$41.15M$39.26M$42.18M$36.42M
Shareholders' equity$18.75M$61.26M$111.28M$201.37M$318.66M
Shares outstanding3.18M3.16M54.94M54.61M54.24M
Cash flow statement
Operating cash flow-$31.51M-$47.96M-$78.26M-$118.21M-$126.88M
Capital expenditure—$34,000———
Free cash flow—-$47.99M———
Investing cash flow$40.22M$54.95M$65.24M$25.20M-$45.81M
Financing cash flow$23,000$8.87M$135,000-$1.35M$166.66M
Depreciation & amortization$728,000$3.08M$3.72M$3.68M$1.54M
Stock-based compensation$3.00M$5.82M$10.92M$18.95M$32.69M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.